castration-resitant | THE "NEW" PROSTATE CANCER INFOLINK

Follow The "New" Prostate Cancer InfoLink news blog on TWITTER or FACEBOOK.
The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
This web site is a service of Prostate Cancer International.

Prostate Cancer International is a non-profit for 2012 as rated by Great NonProfits
Other PCI web sites

El Cáncer de Próstata Latinoamérica
Prostate Cancer Africa
Prostate Cancer Caribbean
Solidarité Prostate InfoLink
The "New" Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Copyright © 2008-11 Prostate Cancer International, Inc.

Update on Phase III trial of tasquinimod in mCRPC

Posted on May 21, 2012 by Sitemaster

According to a media release issued this morning by Active Biotech and Ipsen, the companies have already enrolled 600 out of the 1,200 men with metastatic, castration-resistant prostate cancer (mCRPC) needed to complete the randomized, double-blind Phase III clinical trial of tasquinimod. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resitant, mCRPC, metastatic, tasquinimod | Leave a Comment »

THE "NEW" PROSTATE CANCER INFOLINK

Other PCI web sites

Update on Phase III trial of tasquinimod in mCRPC

Video Interviews

Find Clinical Trials

In a New York Minute

Hot Posts …

… and Archives

Follow “THE "NEW" PROSTATE CANCER INFOLINK”